Boehringer In­gel­heim, OSE Im­munother­a­peu­tics ex­pand part­ner­ship be­yond can­cer

Boehringer In­gel­heim is build­ing on its col­lab­o­ra­tion with OSE Im­munother­a­peu­tics by in­ves­ti­gat­ing two clin­i­cal-stage on­col­o­gy pro­grams in car­dio-re­nal-meta­bol­ic dis­ease and adding a third pre­clin­i­cal can­cer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER